Badar M. Mian, MD

Increased usage of bladder diagrams was observed following implementation of the program.

Dr. Badar M. Mian highlights the safety and efficacy of relugolix, describing the drug as an “exciting new option” for patients with recurrent or advanced prostate cancer.

"In the era of BCG shortage, it would have been highly desirable to demonstrate the efficacy and safety of fewer BCG instillations for high-risk bladder cancer. However, reduced frequency of maintenance BCG instillations is associated with increased risk of cancer recurrence, albeit with fewer adverse effects," writes Badar M. Mian, MD.

"This important trial supports the use of adjuvant chemotherapy after nephroureterectomy for stage T2 or higher cases," writes Badar M M. Mian, MD.

"Death due to prostate cancer was quite rare, with only four men (0.2%) dying of prostate cancer during the study period," writes Badar M. Mian, MD.

"In this era of BCG shortage, we may be forced to develop new standards and alternative strategies for bladder preservation," writes Badar M. Mian, MD.

"Irrespective of treatment, fewer than half of men reported the ability to maintain erections sufficient for intercourse at 5 years," writes Badar M. Mian, MD.

"Even in this selected cohort of men with very low-risk features, stable MRI score was not protective against disease progression during surveillance," writes Badar M. Mian, MD.

"The relevant professional associations in the field of medicine and/or urology must do their part to inform and educate their members about the appropriate use of finasteride and PSA to eliminate avoidable morbidity and mortality from prostate cancer," writes Badar M. Mian, MD.

"It’s critically important to not overemphasize the benefits or overlook the concerns related to new technology or surgical approaches as is too often the case in the marketing campaigns by various centers (both academic and community)," writes Badar M. Mian, MD.

"Of note, the number needed to treat analysis revealed that 18 patients treated with ADT resulted in one patient being diagnosed with Alzheimer’s and 10 patients treated with ADT resulted in one patient with a dementia diagnosis," writes Badar M. Mian, MD.

Patients with CVD taking abiraterone or enzalutamide have a 43% higher risk of hospitalization, according to a recent study.

"There appears to be a strikingly high likelihood of increased morbidity and poor outcomes in patient who are not receiving definitive therapy," writes Badar M. Mian, MD.

"While the safety and feasibility of the renal mass biopsy procedure has been established, if or when to obtain the biopsy remains a topic for active discussion," writes Badar M. Mian, MD.

"This report brings to light an often-suspected but previously undocumented clinical issue in great and alarming detail," says Badar M. Mian, MD.

"In this study, even if only the higher risk subgroup (unfavorable PSMs and advanced stage/grade) were to receive adjuvant treatment, nearly 75% of patients may potentially be overtreated," writes Badar M. Mian, MD.

"Despite improvements in the diagnostic markers and imaging, overdiagnosis and particularly overtreatment continue to pose a challenge for the urologic community," writes Badar M. Mian, MD.

"Biochemical recurrence after radical prostatectomy may occur in 20% to 50% of cases and salvage radiation therapy is considered the best treatment in most cases. But the questions about whether to add androgen deprivation therapy, as well as its dose and duration, remain subjects of active clinical debate," writes Badar M. Mian, MD.

Surgery was associated with improved cancer-specific and overall mortality compared with radiation therapy, according to a recent study.

"This study highlights the need for each practice to perform a self-audit of its AS protocol and take all necessary measures to ensure that patients are not lost during the monitoring period," writes Badar M. Mian, MD.

Phase III data indicate benefit only for a subset of patients.

"Proper patient selection, including those with low-/intermediate-risk disease, is paramount," writes Badar M. Mian, MD.

"While there was no further reduction of prostate cancer risk after finasteride was discontinued, there was also no evidence that stopping finasteride resulted in more cases of prostate cancer," writes Badar M. Mian, MD.

"While these results cannot be extrapolated to men with very high PSA level or advanced clinical stage, the study provides appropriate benchmark data for our contemporary patients with high-risk clinically localized prostate cancer," writes Badar M. Mian, MD.

"Despite the potential benefits (fewer biopsies, less cost), the proposed approach to cancer detection and biopsy-that can miss 16%-40% of existing csPCa-may be difficult to justify for all patients," writes Badar M. Mian, MD.

Study findings bolster the idea that frequent repeat biopsies are unnecessary.

"This important study provides strong validation of the utility of multiparametric MRI of the prostate prior to initial biopsy," writes Badar M. Mian, MD.

"While improving local control seems to be important, especially in those with high-risk features, it’s not clear whether adjuvant EBRT is necessarily better than early salvage EBRT," writes Badar M. Mian, MD.

"The management of prostate cancer always requires caution to safeguard against avoidable risks from both the treatment and the monitoring protocol," writes Badar M. Mian, MD.

"In the end, it is up to the surgeons who wish to continue to perform these robotic procedure to demonstrate their cost-effectiveness," writes Badar M. Mian, MD.